UA86924C2 - Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина - Google Patents

Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина

Info

Publication number
UA86924C2
UA86924C2 UA20041008558A UA20041008558A UA86924C2 UA 86924 C2 UA86924 C2 UA 86924C2 UA 20041008558 A UA20041008558 A UA 20041008558A UA 20041008558 A UA20041008558 A UA 20041008558A UA 86924 C2 UA86924 C2 UA 86924C2
Authority
UA
Ukraine
Prior art keywords
melatonin
barbiturate
term potentiation
short term
intended
Prior art date
Application number
UA20041008558A
Other languages
English (en)
Ukrainian (uk)
Inventor
Нава Зисапель
Original Assignee
Ньюрим Фармасьютикалз (1991) Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA86924(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ньюрим Фармасьютикалз (1991) Лтд. filed Critical Ньюрим Фармасьютикалз (1991) Лтд.
Publication of UA86924C2 publication Critical patent/UA86924C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается использования мелатонина в производстве лекарственного средства обычного высвобождения или пролонгированного высвобождения для краткосрочного усиления снотворного эффекта на человеческий организм, по крайней мере, одного соединения, выбранного из группы снотворных средств, которые не являются барбитуратами или производными бензодиазепина, и являются модуляторами рецептора ГАМК-А, при условии, что такое лекарственное средство обычного высвобождения содержит количество мелатонина, достаточное для усиления снотворного эффекта указанного, по крайней мере, одного соединения при применении указанного, по крайней мере, одного соединения в таком количестве, что, если бы оно применялось к человеку при отсутствии мелатонина, было бы субтерапевтическим количеством.
UA20041008558A 2002-04-28 2003-03-20 Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина UA86924C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds

Publications (1)

Publication Number Publication Date
UA86924C2 true UA86924C2 (ru) 2009-06-10

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041008558A UA86924C2 (ru) 2002-04-28 2003-03-20 Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина

Country Status (30)

Country Link
US (1) US20050175692A1 (ru)
EP (1) EP1494650B1 (ru)
JP (1) JP2005527583A (ru)
KR (1) KR101000624B1 (ru)
CN (1) CN100386070C (ru)
AR (1) AR039232A1 (ru)
AT (1) ATE507831T1 (ru)
AU (1) AU2003227304B2 (ru)
BR (1) BR0308762A (ru)
CA (1) CA2477516C (ru)
DE (1) DE60336999D1 (ru)
DK (1) DK1494650T3 (ru)
EA (1) EA007954B1 (ru)
ES (1) ES2366116T3 (ru)
GT (1) GT200300064A (ru)
HK (1) HK1075616A1 (ru)
HN (1) HN2003000115A (ru)
IL (1) IL149377A (ru)
IS (1) IS2858B (ru)
MX (1) MXPA04009893A (ru)
NO (1) NO332525B1 (ru)
NZ (1) NZ536298A (ru)
PE (1) PE20040161A1 (ru)
PL (1) PL209922B1 (ru)
PT (1) PT1494650E (ru)
TW (1) TW200305404A (ru)
UA (1) UA86924C2 (ru)
UY (1) UY27753A1 (ru)
WO (1) WO2003086352A1 (ru)
ZA (1) ZA200407563B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技（北京）有限公司 一种美乐托宁缓释剂、其制备方法及其应用
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP2570126B1 (en) * 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
ES2828034T3 (es) * 2016-10-31 2021-05-25 Neurim Pharma 1991 Minicomprimidos de melatonina y método de fabricación de los mismos
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
BR9607169A (pt) * 1995-02-01 1997-11-11 Neurim Pharma 1991 Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas
CN100443480C (zh) * 1996-03-08 2008-12-17 武田药品工业株式会社 三环化合物及其制备和用途
WO1997037670A1 (en) * 1996-04-10 1997-10-16 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
DE69728883T2 (de) * 1996-07-17 2005-04-07 Merck & Co., Inc. Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
EP1100508B8 (en) * 1998-06-09 2004-01-07 Takeda Chemical Industries, Ltd. Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
CN1131030C (zh) * 1999-03-18 2003-12-17 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
HUP0203437A3 (en) 1999-03-22 2003-07-28 Immugen Pharmaceuticals Inc So Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Also Published As

Publication number Publication date
US20050175692A1 (en) 2005-08-11
CN1646098A (zh) 2005-07-27
AU2003227304A1 (en) 2003-10-27
JP2005527583A (ja) 2005-09-15
KR101000624B1 (ko) 2010-12-10
ZA200407563B (en) 2005-11-30
EP1494650B1 (en) 2011-05-04
CN100386070C (zh) 2008-05-07
BR0308762A (pt) 2005-01-11
CA2477516C (en) 2012-12-11
EP1494650A4 (en) 2006-07-12
CA2477516A1 (en) 2003-10-23
PE20040161A1 (es) 2004-03-22
IL149377A0 (en) 2009-02-11
EA007954B1 (ru) 2007-02-27
DE60336999D1 (de) 2011-06-16
AU2003227304A2 (en) 2005-04-14
IL149377A (en) 2012-10-31
AR039232A1 (es) 2005-02-09
EP1494650A1 (en) 2005-01-12
KR20040101406A (ko) 2004-12-02
PL372867A1 (en) 2005-08-08
IS2858B (is) 2013-12-15
DK1494650T3 (da) 2011-08-08
ES2366116T3 (es) 2011-10-17
TW200305404A (en) 2003-11-01
WO2003086352A1 (en) 2003-10-23
AU2003227304B2 (en) 2007-12-06
MXPA04009893A (es) 2005-06-17
ATE507831T1 (de) 2011-05-15
UY27753A1 (es) 2003-05-30
GT200300064A (es) 2003-11-26
HN2003000115A (es) 2004-04-20
NZ536298A (en) 2008-09-26
PL209922B1 (pl) 2011-11-30
IS7492A (is) 2004-10-07
PT1494650E (pt) 2011-08-18
HK1075616A1 (en) 2005-12-23
NO332525B1 (no) 2012-10-08
EA200401331A1 (ru) 2005-04-28
NO20043576L (no) 2004-12-22

Similar Documents

Publication Publication Date Title
UA86924C2 (ru) Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
HK1090936A1 (en) Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
HUP0002935A2 (hu) Gyomorban visszatartott, szabályozott hatóanyag kibocsátású mikrogömböcskék javított gyógyszeradagolás elősegítésére
WO2005120393A3 (en) Implantable device for drug delivery and improved visibility
AU2003245368A1 (en) Delivery system for flowable medicinal or therapeutic substances
AU2003295614A1 (en) Delivery of pharmaceutical agents via the human insulin receptor
GB0313604D0 (en) Delivery device for powdered medicament
EP2409569A3 (en) Method for administering GLP-1 molecules
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
IL188774A0 (en) Compositions for delivery of drug combinations
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
AU2002302890A1 (en) Hydrodynamically balancing oral drug delivery system with biphasic release
MXPA05001607A (es) Forma galenica para suministro de ingredientes activos dirigido al colon.
ES2189252T3 (es) Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide.
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
MX2007005040A (es) Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central.
TN2009000119A1 (en) Combination drug
AU2003228236A1 (en) Dynamic time metered delivery
CA2585754C (en) Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
MA27418A1 (fr) Ensemble de distribution de medicament.
DE60319802D1 (de) Sedierende nicht-benzodiazepin-formulierungen
AU2003275006A8 (en) Aerosol drug delivery system employing formulation pre-heating